Champions Oncology, Inc. (Champions)

Oncology Corporate Profile

HQ Location

One University Plaza, Suite 307
Hackensack, NJ 7601

Company Description

Champions Oncology, Inc. (formerly Champions Biotechnology, Inc) is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor.

Website: http://www.championsoncology.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TumorGraft Technology PlatformVarious cancer typesDevelopment

View additional information on product candidates here »

Source: http://www.championsoncology.com/

Recent News Headlines

Novartis Highlights CTL019 Data Showing Its Potential in the Treatment of Specific Types of Hard-To-Treat Non-Hodgkin Lymphoma

6/1/2015 06:02 pm

(Novartis) June 1, 2015 - Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma

Amgen's Breakaway From Cancer® Announces Winners Of Its Nationwide Search For Champions In The Fight Against Cancer

5/13/2015 12:09 pm

(MarketWatch) May 12, 2015 - Ten champions will join cancer survivor Joan Lunden at the overall finish of the 10th edition of the Amgen Tour of California.

Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer

3/27/2015 11:25 am

(MarketWatch) Mar 26, 2015 - Amgen today announced that breast cancer survivor Joan Lunden has been named 2015 Honorary Breakaway from Cancer® Champion as part of a nationwide search to identify 10 Champions who have made a positive impact in their community.

Icahn School of Medicine at Mount Sinai and Champions Oncology Initiate Study Evaluating TumorGrafts' Ability to Predict Treatment Benefit in Patients with Triple-Negative Breast Cancer

6/17/2014 12:21 pm

(MarketWatch) June 17, 2014 - Icahn School of Medicine at Mount Sinai and Champions Oncology today announced the initiation of a clinical trial evaluating the use of Champions TumorGrafts® in 100 patients with triple-negative breast cancer.

Icahn School of Medicine at Mount Sinai and Champions Oncology Initiate Study Evaluating TumorGrafts' Ability to Predict Treatment Benefit in Patients with Triple-Negative Breast Cancer

6/17/2014 07:02 am

(MarketWatch) June 17, 2014 - Icahn School of Medicine at Mount Sinai and Champions Oncology today announced the initiation of a clinical trial evaluating the use of Champions TumorGrafts® in 100 patients with triple-negative breast cancer.

Obama Proposes Third Year of Medicaid-Medicare Pay Parity

3/6/2014 12:00 pm

(Medscape Medical News) Mar 5, 2014 - President Barack Obama yesterday released a budget for fiscal 2015 that delighted champions of primary care, even as Congressional Republicans called the overall dollar figures "unserious" and "irresponsible."

CNIO Team Explains Lower Cancer Incidence Rate in Patients Experiencing Brain and Nervous System Diseases

2/21/2014 11:01 am

(CNIO [Madrid, Spain]) Feb 20, 2014 - Epidemiological studies demonstrate that diseases of the central nervous system such as Alzheimer, Parkinson and schizophrenia protect against cancer.

Champions Oncology and Teva Sign a Discovery and Drug Development Partnership

9/13/2013 11:24 am

(Yahoo! Finance) Sep 12, 2013 - Champions Oncology Inc. today announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries LTD which will utilize Champions TumorGraft(TM) technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds.

Champions Oncology and Teva Sign a Discovery and Drug Development Partnership

9/13/2013 11:02 am

(Yahoo! Finance) Sep 12, 2013 - Champions Oncology Inc. today announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries LTD which will utilize Champions TumorGraft(TM) technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds.

Champions Oncology Receives Regulatory Approval from New York State Department of Health

9/11/2013 11:33 am

(Champions) Sep 10, 2013 - Champions Oncology, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it has received a clinical laboratory permit from the New York State Department of Health to provide its innovative Champions TumorGraft test to patients in New York.

Champions Oncology Receives Regulatory Approval from New York State Department of Health

9/11/2013 11:03 am

(Champions) Sep 10, 2013 - Champions Oncology, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it has received a clinical laboratory permit from the New York State Department of Health to provide its innovative Champions TumorGraft test to patients in New York.

Four Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California

5/3/2013 11:45 am

(CNNMoney) May 1, 2013 - Amgen today announced that four individuals who are an inspiration and have made a difference for others affected by cancer have been selected as Breakaway from Cancer® Champions.

Glaxo-Theravance Lung Drug Gains Backing of FDA Advisers

4/18/2013 12:00 pm

(Bloomberg) Apr 17, 2013 - GlaxoSmithKline Plc and Theravance Inc.’s Breo Ellipta should be approved to treat a lung disorder that is the third-leading cause of death in the U.S., advisers to the Food and Drug Administration said.

Amgen Announces Call For Nominations For 2013 Breakaway From Cancer® Champions

2/8/2013 12:30 pm

(San Francisco Business Times) Feb 8, 2013 - Four inspirational individuals making a positive impact for those affected by cancer to be honored at the Amgen Tour of California.

Champions Oncology Announces Geographic Expansion

12/13/2012 11:59 am

(iStockAnalyst) Dec 13, 2012 - Champions Oncology, Inc., a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today the expansion of its personalized oncology services into the Asian market.

Champions Oncology Announces Geographic Expansion

12/13/2012 11:05 am

(iStockAnalyst) Dec 13, 2012 - Champions Oncology, Inc., a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today the expansion of its personalized oncology services into the Asian market.

Study: Children Abused by Parents Face Increased Cancer Risk

7/18/2012 11:05 am

(Purdue University) July 17, 2012 - Frequent abuse by a parent can increase a child's cancer risk in adulthood, and the effects are especially significant when mothers abuse their daughters and fathers abuse their sons, according to new research from Purdue University.

Inquiry of Wilms Tumor Renewed

9/16/2011 11:04 am

(The Times Herald [Port Huron, MI]) Sept 15, 2011 - An investigation into a possible cancer cluster is expected to pick up next month.